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COMMENTARY
Phasing in on the cell cycle
Steven Boeynaems1,2,3* , Peter Tompa4,5 and Ludo Van Den Bosch1,2
Abstract 
Just like all matter, proteins can also switch between gas, liquid and solid phases. Protein phase transition has claimed 
the spotlight in recent years as a novel way of how cells compartmentalize and regulate biochemical reactions. 
Moreover, this discovery has provided a new framework for the study of membrane-less organelle biogenesis and 
protein aggregation in neurodegenerative disorders. We now argue that this framework could be useful in the study 
of cell cycle regulation and cancer. Based on our work on phase transitions of arginine-rich proteins in neurodegener-
ation, via combining mass spectroscopy with bioinformatics analyses, we found that also numerous proteins involved 
in the regulation of the cell cycle can undergo protein phase separation. Indeed, several proteins whose function 
affects the cell cycle or are associated with cancer, have been recently found to phase separate from the test tube to 
cells. Investigating the role of this process for cell cycle proteins and understanding its molecular underpinnings will 
provide pivotal insights into the biology of cell cycle progression and cancer.
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Background
Compartmentalization is a key feature of life. The cell 
membrane defines the context of what is living and what 
is not. Yet, this is only the first stage of the spatial organi-
zation of living matter. Cells, and in particularly eukary-
otes, are further divided in subcompartments termed 
organelles, each of them carrying out specific biochemi-
cal reactions. These organelles can be roughly divided 
in two classes: membrane-bound and membrane-less. 
Whereas the processes behind the formation of mem-
brane-bound vesicles have been relatively well-studied, 
the biogenesis and properties of their membrane-less 
counterparts remained elusive.
Membrane-less organelles (e.g. the nucleolus, stress 
granules, …) often consist of protein and RNA. Yet how 
does a cell concentrate these biomolecules without a 
membrane barrier? In recent years the phenomenon of 
liquid–liquid phase separation was found to underlie 
the biogenesis of these compartments [1–9]. Multiva-
lent interactions predominantly mediated by intrinsically 
disordered and low complexity domains drive the spon-
taneous demixing of the RNA binding proteins involved 
[1–10]. This demixing results in the formation of liquid-
like protein droplets or protein hydrogels, and depends 
on specific in  vitro conditions, such as concentration, 
salt and temperature [1–9]. Interestingly, such test-tube 
phases are highly reminiscent of cellular RNA granules, 
suggesting that protein phase transition might indeed 
be the physical basis of the biogenesis of membrane-
less organelles [1, 7, 8, 11]. However, these dynamic test 
tube assemblies seem to spontaneously mature to a more 
solid-like state [7, 8, 12–14], suggesting that they could 
act as stepping stones towards protein aggregation. 
Indeed, membrane-less organelles have been suspected 
to serve this role in some neurodegenerative disorders 
[15, 16].
For example, amyotrophic lateral sclerosis (ALS) is 
an adult-onset neurodegenerative disorder character-
ized by the aggregation of RNA binding proteins (RBPs) 
in the central nervous system [17]. Based on similarities 
in protein content between RBP aggregates and stress 
granules, these membrane-less organelles have been sug-
gested as seeds for pathological aggregation of RBPs in 
patients [15, 16]. However, why these proteins undergo 
this liquid-to-solid switch during aging is unknown. Rare 
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disease mutations found in some of these proteins make 
them more aggregation-prone [7, 8, 13], yet these cases 
do not explain why the wildtype proteins also aggregate 
in the majority of ALS cases. Hexanucleotide repeat 
expansions in the C9orf72 gene are the most common 
genetic cause of ALS [18, 19], and recent evidence points 
at unconventional dipeptide repeat (DPR) peptides 
derived from the expanded repeat RNA as a major patho-
genic species in the disease [20–25]. While five different 
DPRs are formed, two arginine-rich ones (i.e. glycine–
arginine and proline–arginine, or GR and PR), are highly 
toxic in disease models [20–25]. We and others have 
recently found that these arginine-rich DPRs can phase 
separate in the presence of RNA [25]. Additionally, these 
toxic peptides promote a liquid-to-solid switch of stress 
granules in cells [25, 26]. Hence, providing an explana-
tion why the involved RBPs start to aggregate in the most 
common genetic form of the disease.
Main text
Proteins involved in cell cycle phase separate in vitro
We have extensively characterized our PR-RNA granule 
system and argue its usefulness as a test tube model for 
protein phase separation [26]. To identify cellular pro-
teins prone to arginine-mediated phase separation, we 
performed mass spectrometry (MS) [27] (see Fig.  1). 
We incubated soluble HeLa cell lysate, cleared from the 
insoluble fraction, with PR peptide. This resulted instan-
taneously in phase separation of PR with cellular pro-
teins, observed as a clouding of the sample. Through 
mild centrifugation we collected these phase separated 
proteins into a pellet, which we showed was dependent 
on both weak liquid-like and more stable solid-like inter-
actions [27]. Such a stable core/liquid shell topology is 
also observed for membrane-less organelles in living cells 
[11]. We identified 874 proteins in our sample, which 
were enriched for RBPs and proteins involved in stress 
granule metabolism, hereby confirming our observations 
from cells where we found that PR targets and perturbs 
stress granules [27].
Interestingly though, further analysis in follow-up 
work showed that our PR dataset is also highly enriched 
for proteins involved in the regulation of the cell cycle 
(GO:0000278; fold enrichment  =  3.83, p  =  2.93E−23, 
Fisher Exact Bonferroni). In Table  1 we provide an 
overview of some cell cycle proteins (KEGG pathway: 
hsa04110) that we identified in our MS experiment. This 
finding suggests that phase separation could also play 
a role in the regulation of this process. A common fea-
ture of proteins that undergo phase separation is struc-
tural disorder [10]. Indeed, proteins involved in cell cycle 
regulation are on average more disordered (IUPred score; 
median fold change =  1.69, p  <  1.00E−4, Mann–Whit-
ney) compared to the proteome. Besides being mostly 
intrinsically disordered, phase separating proteins also 
often show low sequence complexity, as exemplified by 
prion-like domains [28] (rich in uncharged polar amino 
acids and glycine) and arginine-rich domains [29]. Again, 
cell cycle regulatory proteins are enriched for both prion-
like domains (fold enrichment  =  1.39, p  =  4.90E−02, 
binomial test) and arginine-rich domains (≥ 6 R-motifs/
protein; fold enrichment  =  2.44, p  =  9.33E−15, bino-
mial test) compared to the proteome. Besides these 
typical protein characteristics, several proteins that are 
known to phase separate also affect the regulation of 
the cell cycle (Table 2). Additionally, proteins regulating 
or affecting (even indirectly) the cell cycle are enriched 
in several known membrane-less organelles (Fig.  2a). 
Fig. 1 Identification of the phase separating proteome. Cleared cell lysate was incubated with poly-PR peptide to induce phase separation of cel-
lular proteins. Phase separated proteins were precipitated by mild centrifugation and subjected to mass spectrometry. Identified proteins included 
stress granule factors and other membrane-less organelle components, but surprisingly as well proteins annotated as implicated in the regulation 
of the cell cycle
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Interestingly, some of these organelles also have been 
shown to dynamically change over the course of the cell 
cycle, as exemplified by the nucleolus, purinosome and 
centrosome [30–32]. Given that we found numerous 
cell cycle proteins in our MS dataset, and based on their 
physical characteristics and targeting to membrane-less 
compartments, we argue that there could be a previously 
unappreciated role for protein phase transition in the 
regulation and execution of the cell cycle.
How could membrane‑less organelles be involved in the 
cell cycle and cancer?
We have shown that proteins involved in the regula-
tion of the cell cycle are enriched for features commonly 
associated with phase separation, and many of these pro-
teins are components of membrane-less organelles. This 
begs the question how membrane-less organelles could 
be functionally implicated in the regulation of the cell 
cycle? What purpose do they serve, and are they altered 
in cancer?
Compartmentalization has been known to serve dif-
ferent functions: (1) Catalyzing biochemical reactions by 
concentrating reaction compounds, (2) shielding compo-
nents from each other by localization in different com-
partments, (3) storage of biomolecules for later use, and 
(4) signal amplification. First, the laws of chemistry dic-
tate that at higher concentrations of the reaction compo-
nents, the reaction efficiency will increase. It seems that 
exactly this is the function of the pericentriolar mate-
rial. This membrane-less organelle concentrates tubulin 
monomers, which are subsequently efficiently nucleated 
and grown into microtubules [33]. Secondly, chromatin 
architecture is known to be linked to the cell cycle [34]. 
Recently, two groups reported that heterochromatin 
domains form also by a process of phase separation [35, 
36], showing that this process is key in regulating chro-
matin architecture. Additionally, during mitosis a spe-
cific disordered protein associates with the compacted 
DNA and acts as a biological surfactant to prevent the 
condensed sister chromatids from sticking together [37]. 
Table 1 Cell cycle proteins identified in the mass spec experiment
Gene name Protein name Role in cell cycle
CDC5L Cell division cycle 5-like Cell cycle progression
CDC37 Cell division cycle 37 Cell cycle progression
CDC42 Cell division cycle 42 homolog Kinetochore complex
CDC73 Cell division cycle protein 73 homolog Cell cycle progression
CDK11A Cyclin-dependent kinase 11A Cell cycle progression
CDK11B Cyclin-dependent kinase 11B Cell cycle progression
CUL4A Cullin-4A Cell cycle progression
CUL4B Cullin-4B Cell cycle progression
HDAC1 Histone deacetylase 1 Cell cycle progression
MAD1L1 Mitotic spindle assembly checkpoint protein MAD1 Spindle-assembly checkpoint
MCM2 DNA replication licensing factor MCM2 DNA replication initiation
MCM3 DNA replication licensing factor MCM3 DNA replication initiation
MCM4 DNA replication licensing factor MCM4 DNA replication initiation
MCM5 DNA replication licensing factor MCM5 DNA replication initiation
MCM6 DNA replication licensing factor MCM6 DNA replication initiation
MCM7 DNA replication licensing factor MCM7 DNA replication initiation
PCNA Proliferating cell nuclear antigen Control of DNA replication
PRKDC DNA-dependent protein kinase catalytic subunit Sensor for DNA damage
RAD21 Double-strand-break repair protein rad21 homolog Cohesin complex
SMC1A Structural maintenance of chromosomes protein 1A Cohesin complex
SMC2 Structural maintenance of chromosomes protein 2 Cohesin complex
SMC3 Structural maintenance of chromosomes protein 3 Cohesin complex
SMC4 Structural maintenance of chromosomes protein 4 Cohesin complex
YWHAB 14-3-3 protein beta/alpha Cell cycle progression
YWHAE 14-3-3 protein epsilon Cell cycle progression
YWHAG 14-3-3 protein gamma Cell cycle progression
YWHAH 14-3-3 protein eta Cell cycle progression
YWHAZ 14-3-3 protein zeta/delta Cell cycle progression
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Upon nuclear envelope formation however, another heli-
cal protein exactly does the opposite, by crosslinking the 
condensed DNA to ensure the formation of one nucleus 
[38]. These findings show that phase separation is key 
in the organization of DNA over the cell cycle. Thirdly, 
upon quiescence due to nutrient-limiting conditions the 
cell’s proteasomes will assemble in cytoplasmic protea-
some storage granules. Upon reentry into the cell cycle, 
these granules disassemble and the proteasome com-
plexes translocate back to the nucleus to carry out their 
function [39]. Lastly, protein phase separation can also 
promote signal amplification. One of the best examples 
illustrating this process is the phase separation of T-cell 
receptors upon stimulation. Their phase separated intra-
cellular domains concentrate signaling molecules to 
generate a robust signaling response activating cellular 
differentiation programs [40].
Besides the regulatory functions of membrane-less 
organelles and protein phase separation in processes 
associated with the cell cycle, they are sometimes also 
altered in cancer. For example, different cancers have a 
reported increase in stress granules and paraspeckles. As 
the increased number of these membrane-less organelles 
has been linked to a poor prognosis for survival [41–43], 
it makes them an interesting therapeutic target. Addi-
tionally, aggregation of different tumor suppressor pro-
teins, including p53, results in their loss of function and 
is a major mechanism in cancer [44]. Compounds pre-
venting its aggregation have been successful in preclinical 
animal models [45], indicating that indeed protein phase 
transitions could be viable therapeutic options.
Phase separation is a novel mechanism of oncogenic 
fusion proteins
Interestingly, several of the disordered proteins prone to 
phase separation are also known to be involved in can-
cer-related fusion events (see Table 2). The most relevant 
examples are FUS and EWS, which are also components 
of stress granules and aggregate in ALS [17]. For example, 
FUS is involved in the chimera FUS-CHOP in liposarco-
mas [46]. EWS on the other hand is found as an EWS–
FLI1 fusion causal for sarcomas and leukemias [47], and 
as an EWS–ATF1 fusion in melanomas [48]. Another 
notable example is nucleophosmin (NPM-1), a key com-
ponent of the nucleolus, which is also part of the NPM-
ALK fusion product in non-Hodgkin’s lymphoma [49]. 
Lastly the nuclear pore protein NUP98 is found in many 
oncogenic fusions involved in leukemias [50].
Several observations confirm that the correlation 
between phase separation and fusion proteins is more 
than coincidental. There are three essential features of 
proteins that prevail in both classes, which suggests a 
causative link between the two cellular processes. First, 
phase separating proteins have a high level of struc-
tural disorder [5, 51], which is also the case with onco-
genic fusion proteins [52]. Second, phase separation 
relies on transient and multivalent protein–protein 
interactions [5], and the same principle holds true for 
Table 2 Phase separated proteins whose function affects the cell cycle
a  Highlights protein found as oncogenic fusion proteins [46–49, 52]
Protein name Effect on cell cycle Phase separation
Nucleolus
 FIBL Knockdown reduces cell growth [57] [12]
 NPM-1a Role in tumorigenesis [58] [12]
Stress granule
 eIF4G2 Knockdown induces apoptosis and impairs proliferation [59] [9]
 FUSa Knockdown impairs cell proliferation [60] [6, 8, 9, 51]
 EWSa Knockdown induces apoptosis and impairs proliferation [61] [2]
 hnRNPA1 Knockdown induces cell cycle arrest [62] [7, 9]
 TDP-43 Overexpression induces cell cycle arrest [63] [64]
 TIA-1 Knockdown promotes cell proliferation [65] [9]
Centrosome
 PCM-1 Involved in cell cycle progression [66] [67]
Purinosome
 PPAT Regulates growth rate via de novo purine biosynthesis [68] [69]
Nuclear pore
 Nup98a Regulates expression cell cycle genes [70] [71]
T-cell receptor
 LAT Regulates T-cell activation and proliferation [72] [40]
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Fig. 2 Proteins regulating or affecting the cell cycle are involved in cellular phase separations. a Overview of different membraneless organelles 
(orange). The fold enrichment of cell cycle proteins (GO:0000278) is shown for each organelle for which the protein content was available. T cell 
signaling (GO:0050852) [40], stress granule [11], nuclear speckle (GO:0016607), RNP granule (GO:0035770), PML body [73], P body (GO:0000932), 
nuclear pore (GO:0005643) [74], nucleolus [75], centrosome (GO:0005813) [76]. APC granules and purinosomes were positive for cell cycle proteins 
APC [77] and PPAT [78] respectively. b Examples of cell cycle proteins found in membrane-less organelles which can undergo phase separation (see 
Table 1). PONDR disorder prediction plots are shown, indicating prevalence of disordered regions in these proteins (score > 0.5). Coiled coil (CC) and 
low complexity domains (letters indicate overrepresented amino acids) are also indicated. Phosphotyrosine residues necessary for receptor cluster-
ing are indicated for LAT
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oncogenic fusions. For example, activation of the onco-
genic NPM-ALK chimera requires transient oligomeriza-
tion mediated by the NPM segment [49], and coiled-coil 
interaction motifs are central to the autoactivation of 
many other oncogenic fusions [52]. Exactly, such pro-
tein–protein interaction domains are enriched in pro-
teins undergoing phase separation (see Fig. 2b). Third, a 
recurrent feature of cellular phase separation is the pres-
ence of RNA and RNA-binding proteins [6, 16]. Again, 
oncogenic fusion proteins are also significantly enriched 
in RNA- and DNA-binding domains [52, 53].
It is believed that these disordered domains act as 
transcription activation domains, and hence drive gene 
expression where the fusion protein interacts with the 
DNA [51, 52]. Recent evidence has shown that the tran-
scriptional activation potential of these disordered 
domains is directly correlated to their ability to phase 
separate. Kwon et al. [54] generated synthetic fusions of 
the FUS low complexity domain and fused it to a GAL4 
DNA binding domain. By making point mutations which 
interfere with the hydrophobic interactions required for 
phase separation, the researchers not only perturbed 
hydrogel formation in the test tube, but also with tran-
scriptional activity of the fusion protein in cells [54]. 
Compellingly, a new study found exactly the same mech-
anism of action in relevant EWS–FLI fusions observed 
in patients [55]. Also in this study there was a direct cor-
relation between the potential to phase separate and to 
activate transcription by these disordered domains [55]. 
Indeed, several groups have shown that the C-terminal 
domain of RNA polymerase II has a strong affinity for 
phase separated disordered domains [51, 54, 56], illus-
trating how local phase separation can recruit the tran-
scriptional machinery to distinct genomic regions and 
drive the oncogenic transformation of cells.
Conclusions
In the last few years, the concept of protein phase sepa-
ration has taken the field of cell biology by storm. This 
physical phenomenon provides a clear framework for the 
understanding of membrane-less organelle biogenesis. 
Moreover, this insight has given us a new view on protein 
aggregation in the context of human disease, and more 
specifically in neurodegenerative disorders. In our previ-
ous experiments on the role of protein phase transition in 
the pathogenesis of ALS, we developed a test tube model 
for the study of this process. Using MS, this simple model 
allowed us to perform a proteome-wide search for proteins 
which could undergo phase separation. Unexpectedly, we 
identified numerous proteins which were directly involved 
in the cell cycle or its regulation. This finding strongly sug-
gests that protein phase separation could be at play in cell 
cycle regulation and associated diseases such as cancer.
To test this hypothesis, we examined in this commen-
tary the physical characteristics of proteins involved in 
cell cycle regulation, and combined this with new insights 
from recent studies in the phase transition field. Not only 
do proteins involved in cell cycle regulation have the 
right physical characteristics for phase separation, we do 
know they are actually enriched in cellular membrane-
less organelles. Lastly, we suggest different mechanisms 
of how membrane-less organelle formation and related 
processes could be functionally involved in cell cycle 
regulation and misregulation in cancer. We postulate that 
there is increasing evidence for such a functional involve-
ment which warrants further experiments to uncover its 
full extent. To conclude, we would like to argue that the 
framework of protein phase separation could be useful to 
the study of the cell cycle in health and disease, and may 
guide the development of novel therapeutic approaches.
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